Diagnostic accuracy of biomarkers of oxidative stress in parapneumonic pleural effusions

European Journal of Clinical Investigation

Volumn 41, Issue 4, 2011, Pages 349-356

  Tsilioni, Irene ^a   Kostikas, Konstantinos ^a   Kalomenidis, Ioannis ^b   Oikonomidi, Smaragda ^a   Tsolaki, Vassiliki ^a   Minas, Markos ^a   Gourgoulianis, Konstantinos I ^a   Kiropoulos, Theodoros S ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Diagnostic accuracy; Empyema; Inflammatory cells; Oxidative stress; Pleural effusion; Pleural infection

Indexed keywords

8 ISOPROSTANE; BIOLOGICAL MARKER; SUPEROXIDE DISMUTASE;

AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIATION; EMPYEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERUM;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; DINOPROST; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLEURAL EFFUSION; PNEUMONIA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SUPEROXIDE DISMUTASE;

EID: 79952513909     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02413.x     Document Type: Article

References (34)

1. Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc 2006;3:75-80.
2. Light RW, Rodriguez RM. Management of parapneumonic effusions. Clin Chest Med 1998;19:373-82.
3. Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med 1980;69:507-12.
4. Light RW. A new classification of parapneumonic effusions and empyema. Chest 1995;108:299-301.
5. Sahn SA. Management of complicated parapneumonic effusions. Am Rev Respir Dis 1993;148:813-7.
6. Tkaczyk J, Vizek M. Oxidative stress in the lung tissue - sources of reactive oxygen species and antioxidant defence. Prague Med Rep 2007;108:105-14.
7. Banerjee AK, Mandal A, Chanda D, Chakraborti S. Oxidant, antioxidant and physical exercise. Mol Cell Biochem 2003;253:307-12.
8. Park HS, Kim SR, Lee YC. Impact of oxidative stress on lung diseases. Respirology 2009;14:27-38.
9. Ciencewicki J, Trivedi S, Kleeberger SR. Oxidants and the pathogenesis of lung diseases. J Allergy Clin Immunol 2008;122:456-68.
10. Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006;533:222-39.
11. Morcillo EJ, Estrela J, Cortijo J. Oxidative stress and pulmonary inflammation: pharmacological intervention with antioxidants. Pharmacol Res 1999;40:393-404.
12. Papageorgiou E, Kostikas K, Kiropoulos T, Karetsi E, Mpatavanis G, Gourgoulianis KI. Increased oxidative stress in exudative pleural effusions: a new marker for the differentiation between exudates and transudates? Chest 2005;128:3291-7.
13. Oikonomidi S, Kostikas K, Kalomenidis I, Tsilioni I, Daenas C, Gourgoulianis K et al. Matrix metalloproteinase levels in the differentiation of parapneumonic pleural effusions. Respiration 2010;80:285-91.
14. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003;138:W1-12.
15. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
16. Kiropoulos TS, Kostikas K, Oikonomidi S, Tsilioni I, Nikoulis D, Germenis A et al. Acute phase markers for the differentiation of infectious and malignant pleural effusions. Respir Med 2007;101:910-8.
17. Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507-13.
18. Davies CW, Gleeson FV, Davies RJ. BTS guidelines for the management of pleural infection. Thorax 2003;58(Suppl 2):ii18-28.
19. Aleman C, Alegre J, Monasterio J, Segura RM, Armadans L, Angles A et al. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions. Clin Sci (Lond) 2003;105:601-7.
20. Kroegel C, Antony VB. Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J 1997;10:2411-8.
21. Gogou E, Hatzoglou C, Chamos V, Zarogiannis S, Gourgoulianis KI, Molyvdas PA. The contribution of ascorbic acid and dehydroascorbic acid to the protective role of pleura during inflammatory reactions. Med Hypotheses 2007;68:860-3.
22. Dalaveris E, Kerenidi T, Katsabeki-Katsafli A, Kiropoulos T, Tanou K, Gourgoulianis KI et al. TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer 2009;64:219-25.
23. Gottschall EB, Wolfe P, Haegele AD, Zhu Z, Rose CS, Sells T et al. Increased urinary 8-isoprostaglandin F(2)alpha is associated with lower plasma selenium levels and lower vegetable and fruit intake in an asbestos-exposed cohort at risk for lung cancer. Chest 2004;125:83S.
24. Lehtonen H, Oksa P, Lehtimaki L, Sepponen A, Nieminen R, Kankaanranta H et al. Increased alveolar nitric oxide concentration and high levels of leukotriene B(4) and 8-isoprostane in exhaled breath condensate in patients with asbestosis. Thorax 2007;62:602-7.
25. Marikovsky M, Nevo N, Vadai E, Harris-Cerruti C. Cu/Zn superoxide dismutase plays a role in angiogenesis. Int J Cancer 2002;97:34-41.
26. Romero PV, Rodriguez B, Martinez S, Canizares R, Sepulveda D, Manresa F. Analysis of oxidative stress in exhaled breath condensate from patients with severe pulmonary infections. Arch Bronconeumol 2006;42:113-9.
27. Antony VB, Mohammed KA. Pathophysiology of pleural space infections. Semin Respir Infect 1999;14:9-17.
28. Chen SC, Chen W, Hsu WH, Yu YH, Shih CM. Role of pleural fluid C-reactive protein concentration in discriminating uncomplicated parapneumonic pleural effusions from complicated parapneumonic effusion and empyema. Lung 2006;184:141-5.
29. Porcel JM, Galindo C, Esquerda A, Trujillano J, Ruiz-Gonzalez A, Falguera M et al. Pleural fluid interleukin-8 and C-reactive protein for discriminating complicated non-purulent from uncomplicated parapneumonic effusions. Respirology 2008;13:58-62.
30. Colice GL, Curtis A, Deslauriers J, Heffner J, Light R, Littenberg B et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest 2000;118:1158-71.
31. Vives M, Porcel JM, Gazquez I, Perez B, Rubio M. Pleural SC5b-9: a test for identifying complicated parapneumonic effusions. Respiration 2000;67:433-8.
32. Heffner JE, Brown LK, Barbieri C, DeLeo JM. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med 1995;151:1700-8.
33. Porcel JM, Vives M, Esquerda A. Tumor necrosis factor-alpha in pleural fluid: a marker of complicated parapneumonic effusions. Chest 2004;125:160-4.
34. Alegre J, Jufresa J, Segura R, Ferrer A, Armadans L, Aleman C et al. Pleural-fluid myeloperoxidase in complicated and noncomplicated parapneumonic pleural effusions. Eur Respir J 2002;19:320-5.